Toward Quantum-Enabled Biomarker Discovery: An Outlook from Q4Bio

Abstract

We present a case study and forward-looking perspective on co-design for hybrid quantum-classical algorithms, centered on the goal of empirical quantum advantage (EQA), which we define as a measurable performance gain using quantum hardware over state-of-the-art classical methods on the same task. Because classical algorithms continue to improve, the EQA crossover point is a moving target; nevertheless, we argue that a persistent advantage is possible for our application class even if the crossover point shifts. Specifically, our team examines the task of biomarker discovery in precision oncology. We push the limitations of the best classical algorithms, improving them as best as we can, and then augment them with a quantum subroutine for the task where we are most likely to see performance gains. We discuss the implementation of a quantum subroutine for feature selection on current devices, where hardware constraints necessitate further co-design between algorithm and physical device capabilities. Looking ahead, we perform resource analysis to explore a plausible EQA region on near/intermediate-term hardware, considering the impacts of advances in classical and quantum computing on this regime. Finally, we outline potential clinical impact and broader applications of this hybrid pipeline beyond oncology.